Browsing by Author "Xie, L"
Now showing 1 - 20 of 30
- Results Per Page
- Sort Options
Conference Object Evaluating the Economic Burden and Health Care Utilization of Coronary Artery Disease in the Us Medi-Cal Population(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object A Comparative Analysis of the Health Care Utilization and Costs of Patients Diagnosed With and Without Liver Cancer in the Us Medicare Population(2017) Ogbomo, A.; Lin, Y.; Keshishian, A; Xie, L; Yuce, H; Başer, Onur...Conference Object Trends in Prevalence and Incidence Rates of Type 2 Diabetes Mellitus in the Medicare Population(2015) Xie, L; Wang, Y; Tan, H; Ogbomo, A; Başer, Onur; Yuce H....Conference Object Comparison of Major-Bleeding Risk and Health Care Costs Among Treatment-Naïve Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin(2015) Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J....Conference Object Comparative Persistence With Antihyperglycemic Agents (aha) Used To Treat Type 2 Diabetes Mellitus (t2dm) in the Real World(2016) Cai, J; Wang, Y; Başer, Onur; Xie, L; Diels, J; Neslusan, C; Chow, W....Conference Object Examine the Burden of Illness of Us Medicare Patients Diagnosed With Cataract(2016) Tan, H; Xie, L; Wang, Y; Yuce H; Başer, Onur...Conference Object Demographic and Socioeconomic Characteristics That Impact Selection of Oral Anticoagulants Among Non-Valvular Atrial Fibrillation Patients(2016) Keshishian, A; Du, J; Xie, L; Yuce H.; Başer, Onur...Conference Object Early Comparison of Major Bleeding, Stroke and Associated Medical Costs Among Treatment-Naive Non-Valvular Atrial Fibrillation Patients Initiating Apixaban, Dabigatran, Rivaroxaban or Warfarin(2015) Alpesh, A; Keshishian, A; Xie, L; Başer, Onur; Price, K; Vo, L; Singh, P; Bruno, A; Mardekian, J; Tan, W; Singhal, S; Patel, C; Odell, K; Trocio J....Conference Object Real-World Comparison of Major Bleeding Risk Among Untreated Non-Valvular Atrial Fibrillation Patients and Those Initiating Apixaban, Dabigatran, Rivaroxaban, or Warfarin(2016) Amin, Alpesh; Keshishian, A; Xie, L; Başer, Onur; Price, K; Lien Vo; Mardekian, J; Mendoza, M; Singhal, S; Patel, C; Odell, K; Trocio J.Background: Recent large randomized controlled trials have shown that novel oral anticoagulants (NOACs) are at least as effective as warfarin for risk reduction of stroke in patients with non-valvular atrial fibrillation (NVAF) and are associated with similar or lower rates of bleeding. The study aim was to compare major bleeding risk among untreated NVAF patients to those initiating apixaban, dabigatran, rivaroxaban or warfarinConference Object Retrospective Analysis of the Economic Burden of Patients Diagnosed With Congestive Heart Failure in the California Medicaid Population(2016) Ogbomo, A; Zhao, Y; Kariburyo, M. Furaha; Xie, L; Yuce, H; Başer, Onur...Conference Object Comparison of All-Cause Mortality Rate and Economic Burden Between Newly Diagnosed Alzheimer’s Disease Patients Who Received Anti-Dementia Treatment Versus Not: a Longitudinal Retrospective Study(2016) Black, CM; Hu, X; Khandker RK; Ambegaonkar, BM; Kariburyo, M. Furaha; Xie, L; Başer, Onur; Yuce, H....Conference Object Pcn62 - Assessing the Economic Burden of Us Medicare Patients Diagnosed With Non-hodgkin's Lymphoma(2015) Xie, L; Keshishian, A; Du, J; Başer, OnurOBJECTIVES: To evaluate the health care resource utilization and economic burdenof non-Hodgkin’s lymphoma (NHL) in the U.S. Medicare population. METHODS:NHL patients were identified (International Classification of Diseases, 9th Revision,Clinical Modification [ICD-9-CM] diagnosis codes 200.xx and 202.xx) using nationalU.S. Medicare claims from January 1, 2009 through December 31, 2011. The first diagnosis date was designated as the index date for the NHL cohort. Control patients of thesame age, region, gender and index year were identified and matched to case patientsbased on baseline Charlson Comorbidity Index (CCI) scores, and were assigned a randomly chosen index date to minimize selection bias. Patients were required to havecontinuous medical and pharmacy benefits 1 year pre- and post-index date. Studyoutcomes, including health care costs and utilizations, were compared between thedisease and comparison cohorts using 1:1 propensity score matching (PSM). RESULTS:A total of 20,254 patients were included in the NHL and comparison cohorts. After1:1 PSM, 4,705 patients were matched from each cohort and baseline characteristicswere balanced. Patients diagnosed with NHL were more likely to utilize health careresources including Medicare carrier (99.0% vs. 70.5%), Durable Medical Equipment(DME, 28.1% vs. 17.7%), Home Health Agency (HHA, 11.4% vs. 4.8%), outpatient visits(80.2% vs. 41.0%), inpatient stays (25.7% vs. 7.4%) and Skilled Nursing Facility (SNF,4.8% vs. 1.7%) and hospice admissions (0.9% vs. 0.3%). Patients diagnosed with NHLalso incurred higher Medicare carrier ($10,603 vs. $1,522), DME ($264 vs. $120), HHA($531 vs. $270), outpatient ($30,013 vs. $4,268), inpatient ($5,762 vs. $1,167), SNF ($875vs. $307), hospice ($197 vs. $67), pharmacy ($1,050 vs. $785) and total costs ($49,296vs. $8,507; p<0.005). CONCLUSIONS: The economic burden and health care resourceutilizations were significantly higher for patients diagnosed with NHL compared topatients without NHL.Conference Object Comparing Health Care Resource Utilization and Costs Among Obese Patients in the Us Medicaid Population(2016) Zhang, Q; Zhao, Y; Keshishian, A; Xie, L; Yuce H.; Başer, OnurObjectives : To evaluate health care resource utilization and costs among obese patients in the U.S. Medicaid population.Conference Object Evaluating the Economic Burden and Health Care Utilization of Anemia in the Us Medicare Population(2016) Tan, H; Xie, L; Başer, Onur; Yuce, H; Wang Y....Conference Object Examination of the Economic Burden of Dyslipidemia in the Veterans Health Administration Population(2016) Keshishian, A; Tan, H; Xie, L; Başer, Onur...Conference Object Assessing Health Care Resource Utilization and Costs Among Us Veterans Diagnosed With Asthma(2016) Ogbomo, A; Tan, H; Kariburyo, F; Xie, L; Başer, Onur...Conference Object Treatment Patterns Among Newly Diagnosed Multiple Myeloma Patients in the United States Veteran Population (2010-2015)(2016) Parikh, K; Pandya, S; Abouzaid, S; Başer, Onur; Xie, L; Patel, MI....Conference Object Assessing the Economic Burden and Health Care Resource Utilization of Us Veterans With Chronic Obstructive Pulmonary Disease(2016) Ogbomo, A; Tan, H; Kariburyo, F; Xie, L; Başer, Onur...Conference Object Examining the Economic Burden and Health Care Utilization of Menopausal Women in the U.s. Medicaid Population(2015) Keshishian, A; Wang, Y; Xie, L; Başer, Onur; Yuce H....Conference Object Evaluation of the Burden of Parkinson’s Disease in Medicare and Linked Long Term Care Populations(2015) Xie, L; Tan, H; Ogbomo, A; Wang, Y; Başer, Onur; Yuce H.Objectives: To examine the economic burden and health care utilization forpatients diagnosed with Parkinson’s disease using linked data from Medicare andthe Long Term Care (LTC) Minimum Data Set (MDS). Methods: Patients wereincluded in the study if they had at least one diagnosis claim for Parkinson’s disease(International Classification of Diseases, 9thRevision, Clinical Modification code 332.xx) during the identification period (01JUL2008-31DEC2010). The first Parkinson’s disease diagnosis claim date was designated as the index date. Patients were requiredto be age ?65 and have continuous health plan enrollment with medical benefitsfor 6 months pre- and post-index date. Residents in a LTC facility were defined asstudy patients using two quarterly assessments recorded in the MDS during the6-month baseline period. Demographic and clinical characteristics and follow-uphealth care costs and utilizations were described. Results: After 1:1 matching,1,620 patients were included in each group (disease and control patients), and thebaseline characteristics were well-balanced. Patients with Parkinson’s diseasewere more likely to have inpatient stays (14.26% vs. 9.51%, p<0.0001), outpatientvisits (47.72% vs. 41.11%, p=0.0002), skilled nursing facility (SNF) visits (20.37% vs.4.51%, p<0.0001), hospice visits (8.64% vs. 1.36%, p<0.0001), and part D pharmacyvisit (62.65% vs. 53.33%, p<0.0001). Compared to control patients, higher all-causehealth care costs were also observed for Parkinson’s disease patients, includinginpatient costs ($2,451 vs. $1,301, p<0.0001), SNF costs ($2,503 vs. $778, p<0.0001),hospice costs ($1,164 vs. $245, p<0.0001), total outpatient costs ($4,477 vs. $1,304,p<0.0001), pharmacy costs ($695 vs. $1,399, p<0.0001) and total costs ($9,775 vs.$5,314, p<0.0001). Conclusions: During a period of 12 months, patients diagnosed with Parkinson’s disease had higher health care utilization and costs thanmatched control patients.
